Scilex holding co

US StockHealth Care

SCLX AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

With insufficient quarterly financial data released by the company, we're unable to provide a rating.

SCLX Current Performance


Scilex holding co


Avg of Sector



Top 10 High Relevance to SCLX

  • ZVRA Zevra therapeutics inc
    Value 3Trend 5Swing Trading 2Whale Interest 2Dividend 1
    See more

SCLX Profile

Scilex Holding Company is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system) 1.8%, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It also focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.

Price of SCLX